Pictet Asset Management (Switzerland)’s Bio-Rad Laboratories Class A BIO Stock Holding History

Pictet Asset Management (Switzerland)’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$3.38M	Sell	8,918 -4,536	-34%	-$1.85M	﹤0.01%	838
2023 Q1	$6.44M	Buy	13,454 +4,614	+52%	+$2.16M	0.01%	724
2022 Q4	$3.72M	Sell	8,840 -500	-5%	-$202K	0.01%	808
2022 Q3	$3.9M	Buy	9,340 +220	+2%	+$110K	0.01%	788
2022 Q2	$4.51M	Sell	9,120 -25,036	-73%	-$13M	0.01%	778
2022 Q1	$19.2M	Sell	34,156 -56,156	-62%	-$33.9M	0.02%	508
2021 Q4	$68.2M	Buy	90,312 +11,207	+14%	+$8.39M	0.07%	292
2021 Q3	$59M	Buy	+79,105	New	+$59.3M	0.07%	305

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Pictet Asset Management (Switzerland)'s BIO Position: Q2 2023 in Review

Pictet Asset Management (Switzerland) reduced its Bio-Rad Laboratories Class A (BIO) stake by 34% in Q2 2023, selling an estimated $1.85M and leaving 8,918 shares worth $3.38M. The position accounts for ﹤0.01% of the portfolio, ranked #838.

Pictet Asset Management (Switzerland) first reported a position in BIO in Q3 2021 and has held it in 8 quarters since. The position peaked at $68.2M in Q4 2021. 469 funds tracked by Wall St. Rank hold BIO as of Q2 2023.

Pictet Asset Management (Switzerland) held 8,918 shares of Bio-Rad Laboratories Class A worth $3.38M as of Q2 2023.
Pictet Asset Management (Switzerland) sold 4,536 Bio-Rad Laboratories Class A shares in Q2 2023, an estimated $1.85M.
Bio-Rad Laboratories Class A made up ﹤0.01% of Pictet Asset Management (Switzerland)'s portfolio in Q2 2023, its #838 holding.
Pictet Asset Management (Switzerland) first reported a position in Bio-Rad Laboratories Class A in Q3 2021 and has held it in 8 quarters since.
Pictet Asset Management (Switzerland)'s Bio-Rad Laboratories Class A position peaked at $68.2M in Q4 2021.
469 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2023.

Based on Pictet Asset Management (Switzerland)'s 13F filing for Q2 2023, filed 10 Aug 2023.